Day: June 25, 2025

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the Australian Patent Office for its Diabetes Neuromodulation technology. Patent number 2019252920, entitled, “Simultaneous Multi-Site Vagus Nerve Neuromodulation For Improved Glycemic Control System And Methods,” will provide protection until April 12, 2039. The Diabetes Neuromodulation system leverages its proprietary vagus nerve block (vBloc™) technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked with obesity. “Type 2 diabetes remains...

Yokneam Illit, Israel, June 25, 2025 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, recently announced the expansion of its Large Motor Unit Action Potential Model (“LMM”) into new potential markets, such as predictive health monitoring and cognitive state analytics. This development will enable the broadening of bio-signal intelligence applications beyond wearables and will offer businesses and healthcare providers access to real-time physiological insights for monitoring health and wellness conditions. This strategic expansion into predictive health monitoring aligns with the rising interest in personalized wellness devices. This interest is now demonstrated at...

New eBee X units enhance capabilities across agriculture, urban planning, and strategic applications WICHITA, Kan., June 25, 2025 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE: UAVS), a leading provider of advanced drone and aerial imaging solutions, announces the sale of two additional eBee X drones to South Korea, expanding the country’s installed base of AgEagle’s eBee drones to more than 100 units. This milestone strengthens AgEagle’s strategic partnership with South Korea and reinforces its position as a leader in the Asia-Pacific drone market. The eBee X, AgEagle’s flagship fixed-wing mapping drone, is engineered for high-precision geospatial data collection and is ideally suited for applications including surveying, mapping, and photogrammetry. This latest sale builds on a well-established fleet, further strengthening...

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. The randomized, double-blind, multicenter study was conducted by Kashiv to assess the efficacy, safety, and immunogenicity of ADL-018 compared to XOLAIR® in patients with Chronic Idiopathic Urticaria (CIU) or Chronic Spontaneous Urticaria (CSU) who remained symptomatic despite treatment...

Combination cohort initiated following successful review of monotherapy cohort Over 100 participants dosed to-date in monotherapy cohort Priority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer Data update on schedule for later this year  NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab). “We are very pleased to reach this important milestone and with such an encouraging...

BOSTON, June 25, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that three late-breaking abstracts have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. In a live oral presentation, Susan Phillips, M.D., Pediatric Endocrinology, University of California San Diego/Rady Children’s Hospital, San Diego, will present data from Rhythm’s pivotal Phase 3 TRANSCEND trial evaluating setmelanotide in the largest randomized, placebo-controlled trial in acquired hypothalamic obesity to date.Efficacy and Safety of Setmelanotide in Acquired Hypothalamic Obesity: Results from a Double-Blind,...